

Ben Scruggs, CEO of Altis Biosystems: Building the Gut Model That Predicts Which Drugs Actually Work
Ben Scruggs, CEO of Altis Biosystems, joins me to talk about building human gut models that help pharma, biotech, and nutrition companies predict how a drug or ingredient will actually behave in the body before it ever reaches a patient. The conversation covers what an epithelial barrier is and why the gut is such an overlooked bottleneck in drug development, how Altis's technology is being used for absorption studies, inflammation research, and toxicity screening, and why GLP-1 drugs make such a compelling test case for the company's platform. Just as much of the episode is about Ben's own path: trained as a cell biologist, he spent close to a decade as a venture investor at Hatteras Venture Partners before stepping into the CEO role at Altis, a UNC spinout, about three years ago. He talks candidly about what surprised him most moving from advising founders to running a company himself, including the realization that most of the job is selling, not science. Altis Biosystems has scaled from testing a few dozen compounds at a time to routinely screening thousands, using automation and robotics to keep pace with customer demand, and Ben shares where he sees the technology heading next, well beyond the gut. Timestamps 00:00 Cold open & sponsor thank-yous 01:40 Scot's pre-show intro: today's guest, Ben Scruggs of Altis Biosystems 03:33 Episode starts 03:49 How Scot and Ben know each other 04:25 Ben's background: PhD in cell biology, postdoc in genomics 05:28 The pivot into venture investing at Hatteras Venture Partners 06:43 How UNC connections led Ben to Altis Biosystems 09:24 Inside Hatteras Venture Partners: 25 years, 100+ investments 13:06 Making the leap from investor to CEO 15:15 What Altis Biosystems actually does 16:34 What is an epithelial barrier, and why it matters 17:32 The three markets: absorption, inflammation, and toxicity 19:58 Why GLP-1 drugs are the ultimate bioavailability test 20:25 Altis's dual business model: full-service CRO vs. self-serve kits 23:29 Defining bioavailability 24:18 Beyond pharma: nutrition and CPG customers 28:37 The UNC tech-transfer story behind Altis 30:00 Advice for investors considering the jump to operator 31:42 The most underrated founder skill: selling 33:01 What's next: expanding beyond the gut 37:30 Scaling from dozens to thousands of compounds 41:39 Where to learn more about Altis Biosystems 42:10 Thanks and credits Where to Find Ben Scruggs: LinkedIn: https://www.linkedin.com/in/benjaminscruggs/ Altis Biosystems: https://www.altisbiosystems.com/ Where to Find Scot Wingo: LinkedIn: https://www.linkedin.com/in/thescotwingo/ Tweener Times: https://www.tweenertimes.com/ X: https://x.com/scotwingo --- This episode of Triangle Tweener Talks is hosted by Scot Wingo, presented and produced by NC Tweener Fund, with creative assets and design support from Walk West. We couldn’t share posts like this without our amazing sponsors: Platinum: NC IDEA: https://ncidea.org Gold Sponsors: - Balentine: https://www.balentine.com/triangle-entrepreneurs - EisnerAmpner: https://www.eisneramper.com - Robinson Bradshaw: https://www.robinsonbradshaw.com Silver Sponsors: - Automated Consulting Group: https://automated.co - Bank of America: https://business.bofa.com/en-us/content/technology-industry-group.html ------ Triangle Tweener Talks is sponsored by: Atomic Object: https://atomicobject.com/


















